Compare Amphastar Pharmaceuticals Inc (AMPH) vs EHang Holdings Ltd - ADR (EH) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

EHang Holdings (EH) trades at $5.59, down 3.45% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $418M, flat year-over-year but sharply lower sequentially due to delivery timing. Despite a high gross margin of 61.53%, net losses persist with a -77.56% margin. Cash flow improved in 2024 but reversed negative in 2025. Recent news highlights volatility, including an 18% surge on June 15, 2026, followed by concerns over Q1 sales missing forecasts.

The outlook remains speculative with significant execution risks amid ongoing losses, though analyst consensus suggests moderate upside to a $6.97 target. Investment opportunity hinges on commercial scaling of eVTOL operations, but high cash burn and competitive pressures pose substantial risks. Sentiment is divided, with 40% sell ratings reflecting skepticism over near-term profitability.